179 related articles for article (PubMed ID: 28072973)
61. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
62. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
63. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
64. Diffuse invasive breast carcinoma of no special type.
Tot T
Virchows Arch; 2016 Feb; 468(2):199-206. PubMed ID: 26521062
[TBL] [Abstract][Full Text] [Related]
65. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
66. The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.
Barısık NO; Keser SH; Gul AE; Sensu S; Kandemir NO; Kucuk HF; Gumus M; Karadayı N
Med Oncol; 2011 Sep; 28(3):703-8. PubMed ID: 20354817
[TBL] [Abstract][Full Text] [Related]
67. Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis.
Adamczyk A; Niemiec J; Ambicka A; Małecki K; Wysocki WH; Mituś J; Ryś J
Pol J Pathol; 2012 Dec; 63(4):228-34. PubMed ID: 23359191
[TBL] [Abstract][Full Text] [Related]
68. [Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].
Zhang B; Liu FF; Ma YJ; Gu F
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):904-9. PubMed ID: 24506959
[TBL] [Abstract][Full Text] [Related]
69. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
[TBL] [Abstract][Full Text] [Related]
70. Are breast cancer molecular classes predictive of survival in patients with long follow-up?
Pracella D; Bonin S; Barbazza R; Sapino A; Castellano I; Sulfaro S; Stanta G
Dis Markers; 2013; 35(6):595-605. PubMed ID: 24288429
[TBL] [Abstract][Full Text] [Related]
71. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
[TBL] [Abstract][Full Text] [Related]
72. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
[TBL] [Abstract][Full Text] [Related]
73. Morphological profile and receptor status in breast carcinoma: an institutional study.
Rao C; Shetty J; Kishan Prasad HL
J Cancer Res Ther; 2013; 9(1):44-9. PubMed ID: 23575073
[TBL] [Abstract][Full Text] [Related]
74. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
75. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
76. [Clinical significance of FOXM1 and Gli-1 protein expression in high-grade ovarian serous carcinoma].
Zhang J; Li ZY; Duan XJ; Fan XM; Liu WN; Li YH
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):904-908. PubMed ID: 27998466
[No Abstract] [Full Text] [Related]
77. Relationship of Epidermal Growth Factor Receptor Expression with Clinical Symptoms and Metastasis of Invasive Breast Cancer.
Han L; Li L; Wang N; Xiong Y; Li Y; Gu Y
J Interferon Cytokine Res; 2018 Dec; 38(12):578-582. PubMed ID: 30431376
[TBL] [Abstract][Full Text] [Related]
78. Immunohistochemical Expressions of Senescence-Associated Secretory Phenotype and Its Association With Immune Microenvironments and Clinicopathological Factors in Invasive Breast Cancer.
Park MH; Choi JE; Kim JR; Bae YK
Pathol Oncol Res; 2021; 27():1609795. PubMed ID: 34267603
[TBL] [Abstract][Full Text] [Related]
79. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.
Bektas N; Haaf At; Veeck J; Wild PJ; Lüscher-Firzlaff J; Hartmann A; Knüchel R; Dahl E
BMC Cancer; 2008 Feb; 8():42. PubMed ID: 18254960
[TBL] [Abstract][Full Text] [Related]
80. [p53 protein expression in HER2-negative breast invasive ductal carcinoma].
Qing Z; Zou W; Luo J; Wen Q; Fan S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 39(10):1016-22. PubMed ID: 25355267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
